written on 12.03.2014
Tags:
,

Novartis and Roche now have France eyeing competition issues

TAGS: ,

Efforts to steer doctors away from off-label use of cancer drug Avastin in favor of the pricier Lucentis for treating sight issues have gotten Swiss drugmakers Roche and Novartis fined by the anticompetition authority in Italy, where prosecutors are also taking a look, and now French regulators say they are in the midst of a probe of their own.

Latest Report